Notice: This company has been marked as potentially delisted and may not be actively trading. Ambrx Biopharma (AMAM) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sunlands Technology (NYSE:STG) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comCormorant Global Healthcare Master Fund, LP's Net WorthAugust 31, 2024 | benzinga.com14 Day AMERIBOR Average Rate (^AMBRX)May 24, 2024 | finance.yahoo.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)April 5, 2024 | benzinga.comAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | finanznachrichten.deJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 7, 2024 | markets.businessinsider.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 6, 2024 | globenewswire.comFmr LLC Sells 449,560 Shares of Ambrx Biopharma Inc. (NYSE:AMAM)Fmr LLC decreased its holdings in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 20.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,761,058 shares of the company's stock after selling 44March 5, 2024 | marketbeat.com70,000 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Bought by Monashee Investment Management LLCMonashee Investment Management LLC bought a new position in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 70,000 shares of the company's stock, valuedFebruary 25, 2024 | marketbeat.com3 Stocks to Buy That Are Up 200% or More in 2024February 23, 2024 | investorplace.comIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?February 20, 2024 | msn.comAmbrx Biopharma Inc. (NYSE:AMAM) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned aFebruary 16, 2024 | marketbeat.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMFebruary 12, 2024 | stockhouse.com47,433 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp purchased a new position in Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,433 shares of the company's stock, valued at approximately $February 12, 2024 | marketbeat.comAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMFebruary 10, 2024 | businesswire.comTD Asset Management Inc Grows Stock Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)TD Asset Management Inc lifted its stake in Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 73.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 110,456 shares of the company's stock after purchasing an additional 46,728 shareJanuary 22, 2024 | marketbeat.comAmbrx Biopharma Inc. (NYSE:AMAM) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and four have given a bJanuary 22, 2024 | marketbeat.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPJanuary 20, 2024 | stockhouse.comRobert W. Baird Reiterates "Neutral" Rating for Ambrx Biopharma (NYSE:AMAM)Robert W. Baird reissued a "neutral" rating and issued a $28.00 target price on shares of Ambrx Biopharma in a research report on Tuesday.January 16, 2024 | marketbeat.comJMP Securities Downgrades Ambrx Biopharma (AMAM)January 11, 2024 | msn.comAmbrx Biopharma (NYSE:AMAM) Rating Reiterated by JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Ambrx Biopharma in a report on Wednesday.January 10, 2024 | marketbeat.comAmbrx Biopharma just downgraded at JMP Securities, here's whyJanuary 10, 2024 | realmoney.thestreet.comAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&JJanuary 9, 2024 | finance.yahoo.comAmbrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by B. RileyB. Riley reaffirmed a "neutral" rating and set a $28.00 price objective (up previously from $26.00) on shares of Ambrx Biopharma in a research report on Tuesday.January 9, 2024 | marketbeat.comJ&J to buy cancer therapy developer Ambrx for $2 blnJanuary 8, 2024 | nasdaq.comAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersJanuary 8, 2024 | tmcnet.comJohnson & Johnson: Biotech a shot in the arm for future growth? (AMAM)Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.January 8, 2024 | marketbeat.comCrude Oil Falls Sharply; Ambrx Biopharma Shares Spike HigherJanuary 8, 2024 | markets.businessinsider.comWhy Is Ambrx Biopharma (AMAM) Stock Up 100% Today?January 8, 2024 | investorplace.comJohnson & Johnson to buy Ambrx Biopharma for $2 blnJanuary 8, 2024 | reuters.comAmbrx Announces Sale to Johnson & JohnsonJanuary 8, 2024 | finance.yahoo.comAmbrx Biopharma Inc. (NYSE:AMAM) Given Consensus Rating of "Moderate Buy" by AnalystsAmbrx Biopharma Inc. (NYSE:AMAM - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommenDecember 28, 2023 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Ambrx Biopharma (NYSE:AMAM)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Ambrx Biopharma in a report on Monday.December 21, 2023 | marketbeat.comAmbrix to Join NASDAQ Biotech IndexDecember 14, 2023 | msn.comAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)December 14, 2023 | finance.yahoo.comCommodore Capital LP Has $52.26 Million Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)Commodore Capital LP lowered its position in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 33.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,175,000 shares of the company's stock afterDecember 10, 2023 | marketbeat.comOptimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy RatingNovember 29, 2023 | markets.businessinsider.comAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerNovember 28, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)November 14, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)November 14, 2023 | markets.businessinsider.comAmbrx Biopharma (AMAM) Price Target Increased by 8.17% to 25.79November 1, 2023 | msn.comCormorant Asset Management, LP Acquires New Stake in Ambrx Biopharma IncOctober 26, 2023 | finance.yahoo.comRBC Capital Maintains Ambrx Biopharma (AMAM) Outperform RecommendationOctober 24, 2023 | msn.comAmbrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO DataOctober 24, 2023 | seekingalpha.comAmbrx Biopharma: Potential With Recently Released Prostate Cancer DataOctober 23, 2023 | seekingalpha.comAnalyst Ratings for Ambrx BiopharmaOctober 23, 2023 | markets.businessinsider.comAmbrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved TreatmentsOctober 23, 2023 | finance.yahoo.comCancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's WhyOctober 16, 2023 | benzinga.comAmbrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO CongressOctober 16, 2023 | finance.yahoo.com Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now AMAM Media Mentions By Week AMAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMAM News Sentiment▼0.000.60▲Average Medical News Sentiment AMAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMAM Articles This Week▼00▲AMAM Articles Average Week Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News Today KRYS News Today ACLX News Today ADMA News Today IMVT News Today SRRK News Today CRSP News Today DNLI News Today TWST News Today SWTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AMAM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambrx Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
